CN119584980A - 使用mazdutide的治疗方法 - Google Patents

使用mazdutide的治疗方法 Download PDF

Info

Publication number
CN119584980A
CN119584980A CN202380042982.8A CN202380042982A CN119584980A CN 119584980 A CN119584980 A CN 119584980A CN 202380042982 A CN202380042982 A CN 202380042982A CN 119584980 A CN119584980 A CN 119584980A
Authority
CN
China
Prior art keywords
weeks
dosing
compound
administered
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380042982.8A
Other languages
English (en)
Chinese (zh)
Inventor
蔡成行
刘蒙
邓焕
宋柏力
文洁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovent Biologics (Suzhou) Co Ltd
Original Assignee
Innovent Biologics (Suzhou) Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics (Suzhou) Co Ltd filed Critical Innovent Biologics (Suzhou) Co Ltd
Publication of CN119584980A publication Critical patent/CN119584980A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)
CN202380042982.8A 2022-06-01 2023-05-10 使用mazdutide的治疗方法 Pending CN119584980A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2022106226487 2022-06-01
CN202210622648 2022-06-01
PCT/CN2023/093311 WO2023231730A2 (zh) 2022-06-01 2023-05-10 使用mazdutide的治疗方法

Publications (1)

Publication Number Publication Date
CN119584980A true CN119584980A (zh) 2025-03-07

Family

ID=89026916

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380042982.8A Pending CN119584980A (zh) 2022-06-01 2023-05-10 使用mazdutide的治疗方法

Country Status (8)

Country Link
US (1) US20250296973A1 (cg-RX-API-DMAC7.html)
EP (1) EP4534095A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025518227A (cg-RX-API-DMAC7.html)
KR (1) KR20250021331A (cg-RX-API-DMAC7.html)
CN (1) CN119584980A (cg-RX-API-DMAC7.html)
AU (1) AU2023281591A1 (cg-RX-API-DMAC7.html)
CA (1) CA3257926A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023231730A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202617173A (zh) * 2021-06-25 2026-05-01 大陸商信達生物製藥(蘇州)有限公司 Mazdutide的應用
EP4788362A1 (en) * 2023-10-03 2026-08-12 Innovent Biologics (Suzhou) Co., Ltd. Methods of treating diabetes and obesity
WO2026002224A1 (en) * 2024-06-27 2026-01-02 Innovent Biologics (Suzhou) Co., Ltd. Method of treating polycystic ovary syndrome

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI783244B (zh) * 2015-06-22 2022-11-11 美商美國禮來大藥廠 升糖素及glp-1共激動劑化合物
US11419918B2 (en) * 2017-11-06 2022-08-23 Shenzhen Turier Biotech Co., Ltd. Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide
CN111423506B (zh) * 2019-11-08 2023-06-27 成都奥达生物科技有限公司 一种glp-1化合物
TW202617173A (zh) * 2021-06-25 2026-05-01 大陸商信達生物製藥(蘇州)有限公司 Mazdutide的應用

Also Published As

Publication number Publication date
US20250296973A1 (en) 2025-09-25
AU2023281591A1 (en) 2025-01-02
KR20250021331A (ko) 2025-02-12
CA3257926A1 (en) 2025-04-09
EP4534095A2 (en) 2025-04-09
EP4534095A4 (en) 2026-05-27
WO2023231730A3 (zh) 2024-01-25
WO2023231730A2 (zh) 2023-12-07
JP2025518227A (ja) 2025-06-12

Similar Documents

Publication Publication Date Title
RU2546520C2 (ru) Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
US11026999B2 (en) Insulin glargine/lixisenatide fixed ratio formulation
US20250296973A1 (en) Treatment method using mazdutide
US20240293513A1 (en) Use of mazdutide
CN107375909A (zh) 在2型糖尿病患者中预防低血糖症
US20210052703A1 (en) Glp-1 composition for treating obesity and weight management
JP2023510609A (ja) Glp-1および/またはglp-1類似体、ならびにインスリンおよび/またはインスリン類似体を含む併用療法
JP5980466B2 (ja) インスリングラルギン及びメトホルミンへの付加療法を含む2型糖尿病の治療方法
HK40118093A (en) Treatment method using mazdutide
WO2026046202A1 (zh) Glp-1/gip肽或含有其的药物组合物的用途
KR20250095833A (ko) 에페글레나타이드를 유효성분으로 포함하는 약학 조성물 및 이의 투여 요법
WO2026037397A1 (zh) Glp-1类似物的医药用途
TW202529797A (zh) Glp-1類似物治療代謝疾病的方法及醫藥用途
TW202140061A (zh) 用於治療2型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及glp-1協同促效劑
HK40110048A (en) Use of mazdutide
HK40094446A (en) Glp-1 dosing regimen
TW202606762A (zh) 治療t細胞淋巴瘤之組合物及方法
TW202532097A (zh) 治療糖尿病及肥胖的方法
KR20260022330A (ko) 대사 장애의 치료에 사용하기 위한 glp-1 유사체
CA2915413C (en) Insulin glargine/lixisenatide fixed ratio formulation
JP2021528424A (ja) 対象における食後のグルコースレベルをコントロールする方法および使用
HK40039237A (en) Glp-1 analogue beinaglutide composition for treating obesity and weight management
JP2003526675A (ja) 低用量での成長ホルモンの使用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40124454

Country of ref document: HK